A comparative Study to Assess the Efficacy, Safety and Immunogenicity of YLB113 and Enbrel for the Treatment of Rheumatoid Arthritis
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors YL Biologics
- 09 Oct 2017 Status changed from recruiting to completed.
- 05 Oct 2017 The trial has been completed in Latvia (End date: 2017-08-02) according to European Clinical Trials Database record.
- 30 Sep 2017 The trial has been completed in Bulgaria (End Date:2017-08-02).